91 related articles for article (PubMed ID: 22888961)
1. Prognostic significance of pituitary tumour-transforming gene-binding factor (PBF) expression in papillary thyroid carcinoma.
Hsueh C; Lin JD; Chang YS; Hsueh S; Chao TC; Yu JS; Jung SM; Tseng NM; Sun JH; Kuo SY; Ueng SH
Clin Endocrinol (Oxf); 2013 Feb; 78(2):303-9. PubMed ID: 22888961
[TBL] [Abstract][Full Text] [Related]
2. Surgical treatment of papillary and follicular thyroid carcinoma.
Lin JD; Jeng LB; Chao TC; Weng HF; Huang HS
Int Surg; 1996; 81(1):61-6. PubMed ID: 8803709
[TBL] [Abstract][Full Text] [Related]
3. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality.
Chow SM; Law SC; Chan JK; Au SK; Yau S; Lau WH
Cancer; 2003 Jul; 98(1):31-40. PubMed ID: 12833452
[TBL] [Abstract][Full Text] [Related]
4. Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis.
Stratford AL; Boelaert K; Tannahill LA; Kim DS; Warfield A; Eggo MC; Gittoes NJ; Young LS; Franklyn JA; McCabe CJ
J Clin Endocrinol Metab; 2005 Jul; 90(7):4341-9. PubMed ID: 15886233
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
[TBL] [Abstract][Full Text] [Related]
7. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma.
Erdem H; Gündogdu C; Sipal S
Exp Mol Pathol; 2011 Jun; 90(3):312-7. PubMed ID: 21335003
[TBL] [Abstract][Full Text] [Related]
8. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
9. RET proto-oncogene expression of papillary thyroid carcinomas in Thai patients.
Keelawat S; Shuangshoti S; Assanasen T; Thanakit V; Ruangvejvorachai P; Poumsuk U; Wannakrairot P
J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S5-12. PubMed ID: 17718263
[TBL] [Abstract][Full Text] [Related]
10. [Multifocal papillary thyroid carcinoma: clinical analysis of 168 cases].
Lin YK; Sheng JM; Zhao WH; Wang WB; Yu XF; Teng LS; Ma ZM
Zhonghua Wai Ke Za Zhi; 2009 Mar; 47(6):450-3. PubMed ID: 19595234
[TBL] [Abstract][Full Text] [Related]
11. High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma.
Li WF; Wang G; Zhao ZB; Liu CA
Clin Endocrinol (Oxf); 2015 Oct; 83(4):572-80. PubMed ID: 25418110
[TBL] [Abstract][Full Text] [Related]
12. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
13. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer.
Yamamoto S; Tomita Y; Uruno T; Hoshida Y; Qiu Y; Iizuka N; Nakamichi I; Miyauchi A; Aozasa K
Ann Surg Oncol; 2005 Nov; 12(11):925-34. PubMed ID: 16189643
[TBL] [Abstract][Full Text] [Related]
16. VEGF-C and COX-2 expression in papillary thyroid cancer.
Siironen P; Ristimäki A; Narko K; Nordling S; Louhimo J; Andersson S; Haapiainen R; Haglund C
Endocr Relat Cancer; 2006 Jun; 13(2):465-73. PubMed ID: 16728574
[TBL] [Abstract][Full Text] [Related]
17. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
18. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.
Pelttari H; Schalin-Jäntti C; Arola J; Löyttyniemi E; Knuutila S; Välimäki MJ
APMIS; 2012 May; 120(5):380-6. PubMed ID: 22515292
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment of papillary thyroid carcinoma: uni- and multivariate analysis of prognostic factors (TNM staging system included).
Pelizzo MR; Toniato A; Grigoletto R
J Exp Clin Cancer Res; 1997 Sep; 16(3):261-5. PubMed ID: 9387899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
